GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » Institutional Ownership

LungLife AI (LSE:LLAI) Institutional Ownership : 6.69% (As of Jun. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is LungLife AI Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, LungLife AI's institutional ownership is 6.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, LungLife AI's Insider Ownership is 0.38%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, LungLife AI's Float Percentage Of Total Shares Outstanding is 0.00%.


LungLife AI Institutional Ownership Historical Data

The historical data trend for LungLife AI's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI Institutional Ownership Chart

LungLife AI Historical Data

The historical data trend for LungLife AI can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 8.04 8.04 8.04 8.04 8.04 8.04 8.04 6.69 6.69 6.69

LungLife AI Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


LungLife AI (LSE:LLAI) Business Description

Traded in Other Exchanges
N/A
Address
2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320
LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines